Go Pro
OTCMKTS:SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Q4 2025 Earnings Report

Shionogi & Co., Ltd. Unsponsored ADR logo
$9.24 -0.03 (-0.32%)
As of 03:58 PM Eastern

Shionogi & Co., Ltd. Unsponsored ADR EPS Results

Actual EPS
$0.14
Consensus EPS
$0.17
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Shionogi & Co., Ltd. Unsponsored ADR Revenue Results

Actual Revenue
$721.77 million
Expected Revenue
$824.23 million
Beat/Miss
Missed by -$102.45 million
YoY Revenue Growth
N/A

Shionogi & Co., Ltd. Unsponsored ADR Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Shionogi & Co., Ltd. Unsponsored ADR's next earnings date is estimated for Monday, October 26, 2026, based on past reporting schedules.

Conference Call Resources

Shionogi & Co., Ltd. Unsponsored ADR Earnings Headlines

Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.tc pixel
See More Shionogi & Co., Ltd. Unsponsored ADR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shionogi & Co., Ltd. Unsponsored ADR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shionogi & Co., Ltd. Unsponsored ADR and other key companies, straight to your email.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections. The company has also contributed compounds to HIV therapies, including dolutegravir, through its collaboration with ViiV Healthcare. Its research activities have also included central nervous system and pain-related medicines.

Headquartered in Osaka, Shionogi serves patients and healthcare providers in Japan and international markets through its own operations, subsidiaries and commercial partnerships. The company is led by President and Chief Executive Officer Isao Teshirogi. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)s trade in the United States under the symbol SGIOY and represent an interest in the Japanese-listed company.

View Shionogi & Co., Ltd. Unsponsored ADR Profile